Truist Financial Corp Apellis Pharmaceuticals, Inc. Transaction History
Truist Financial Corp
- $62.7 Billion
- Q4 2024
Shares
1 transactions
Others Institutions Holding APLS
# of Institutions
301Shares Held
111MCall Options Held
2.63MPut Options Held
845K-
Avoro Capital Advisors LLC New York, NY12.2MShares$290 Million5.68% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA11.9MShares$283 Million17.73% of portfolio
-
Vanguard Group Inc Valley Forge, PA10MShares$239 Million0.01% of portfolio
-
Morgan Stanley New York, NY9.63MShares$229 Million0.02% of portfolio
-
Black Rock Inc. New York, NY5.8MShares$138 Million0.01% of portfolio
About Apellis Pharmaceuticals, Inc.
- Ticker APLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 109,865,000
- Market Cap $2.61B
- Description
- Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...